GS
BCRX icon

GTS Securities’s BioCryst Pharmaceuticals BCRX Stock Holding History

GTS Securities’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-71,682
Closed -$545K – 4073
2024
Q2 		$443K Buy
71,682
+57,937
+422% +$320K ﹤0.01% 2794
2024
Q1 		$69.8K Sell
13,745
-20,268
-60% -$114K ﹤0.01% 3587
2023
Q4 		$204K Buy
34,013
+10,976
+48% +$63.6K ﹤0.01% 3559
2023
Q3 		$163K Buy
23,037
+4,737
+26% +$34K ﹤0.01% 3478
2023
Q2 		$129K Buy
+18,300
New +$147K ﹤0.01% 1089

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

GTS Securities's BCRX Position: Q3 2024 in Review

GTS Securities sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2024, closing a stake of 71,682 shares — an estimated $545K sold.

GTS Securities first reported a position in BCRX in Q2 2023 and held it in 5 quarters. The position peaked at $443K in Q2 2024. 257 funds tracked by Wall St. Rank hold BCRX as of Q3 2024.

  • GTS Securities reported no remaining BioCryst Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • GTS Securities sold 71,682 BioCryst Pharmaceuticals shares in Q3 2024, an estimated $545K.
  • GTS Securities first reported a position in BioCryst Pharmaceuticals in Q2 2023 and held it in 5 quarters.
  • GTS Securities's BioCryst Pharmaceuticals position peaked at $443K in Q2 2024.
  • 257 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2024.

Based on GTS Securities's 13F filing for Q3 2024, filed 13 Nov 2024.